On September 27, 2024, David Campbell, President and Chief Executive Officer of Janux Therapeutics Inc (JANX, Financial), executed a sale of 25,000 shares of the company at a price of $46.31 per share. This transaction was documented in an SEC Filing. Following this sale, the insider now owns 307,054 shares of Janux Therapeutics Inc.
Janux Therapeutics Inc is engaged in the development of biopharmaceuticals, focusing on the innovation of cancer treatments through Tumor Activated T Cell Engager (TRACTr) technology platforms. These platforms are designed to enhance the body's immune response against tumors, aiming to improve patient outcomes in oncology.
Over the past year, David Campbell has sold a total of 25,000 shares and has not made any purchases of the company's stock. The insider transaction history for Janux Therapeutics Inc shows a trend with 3 insider buys and 8 insider sells over the past year.
Shares of Janux Therapeutics Inc were trading at $46.31 on the day of the transaction, giving the company a market cap of approximately $2.41 billion. According to the GF Value, the stock is currently significantly overvalued, with a price-to-GF-Value ratio of 1.83. The GF Value of $25.30 is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This sale by the insider could be of interest to current and potential investors, providing insight into the insider's perspective on the stock's valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
